Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial

被引：0
|
作者：
Li Zhang
Xin Mei
Zhigang Hu
Bo Yu
Chaoyang Zhang
Yong Li
Kaitai Liu
Xuejun Ma
Jinli Ma
Xingxing Chen
Jin Meng
Wei Shi
Xiaofang Wang
Miao Mo
Zhimin Shao
Zhen Zhang
Xiaoli Yu
Xiaomao Guo
Zhaozhi Yang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Radiation Oncology
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] Shanghai Key Laboratory of Radiation Oncology,Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine
[4] University of Science and Technology of China,Department of Radiotherapy
[5] the Affiliated Jiangyin Hospital of Nantong University,Department of Radiation Oncology
[6] The First Hospital of Quanzhou Affiliated to Fujian Medical University,Department of Oncology
[7] Guizhou Provincial People’s Hospital,Department of Radiation Oncology
[8] The Affiliated Lihuili Hospital of Ningbo University,Department of Cancer Prevention & Clinical Statistics Center
[9] Fudan University Shanghai Cancer Center,Department of Breast Surgery
[10] Fudan University Shanghai Cancer Center,Key Laboratory of Breast Cancer in Shanghai
[11] Fudan University Shanghai Cancer Center,Department of Medical Oncology
[12] Kashgar Prefecture Second People ’ s Hospital,undefined
[13] Xinjiang Uyghur Autonomous Region,undefined
来源：
BMC Cancer | / 24卷
关键词：
Breast cancer; Supraclavicular nodal irradiation; Target volume; Survival outcome; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial
    Yadav, Budhi Singh
    Dahiya, Divya
    Kannan, P.
    Goyal, Shikha
    Laroiya, Ishita
    Irrinki, Santhosh
    Singh, Ngangom Robert
    Sharma, Reena
    TRIALS, 2024, 25 (01)
  • [12] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
    Wang, Shu-Lian
    Fang, Hui
    Song, Yong-Wen
    Wang, Wei-Hu
    Hu, Chen
    Liu, Yue-Ping
    Jin, Jing
    Liu, Xin-Fan
    Yu, Zi-Hao
    Ren, Hua
    Li, Ning
    Lu, Ning-Ning
    Tang, Yu
    Tang, Yuan
    Qi, Shu-Nan
    Sun, Guang-Yi
    Peng, Ran
    Li, Shuai
    Chen, Bo
    Yang, Yong
    Li, Ye-Xiong
    LANCET ONCOLOGY, 2019, 20 (03): : 352 - 360
  • [13] First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
    O'Shaughnessy, J.
    Paul, D.
    Stokoe, C.
    Pippen, J., Jr.
    Blum, J. L.
    Krekow, L.
    Holmes, F. A.
    Vukelja, S.
    Lindquist, D.
    Sedlacek, S.
    Rivera, R.
    Brooks, R.
    McIntyre, K.
    Pluenneke, R.
    Schwartz, J.
    Jones, S.
    Brownstein, C.
    Gilberg, F.
    CANCER RESEARCH, 2010, 70
  • [14] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda
    Katsaros, Dionyssios
    Bessette, Paul
    Haie-Meder, Christine
    Ottevanger, Petronella B.
    Ledermann, Jonathan A.
    Khaw, Pearly
    Colombo, Alessandro
    Fyles, Anthony
    Baron, Marie-Helene
    Jurgenliemk-Schulz, Ina M.
    Kitchener, Henry C.
    Nijman, Hans W.
    Wilson, Godfrey
    Brooks, Susan
    Carinelli, Silvestro
    Provencher, Diane
    Hanzen, Chantal
    Lutgens, Ludy C. H. W.
    Smit, Vincent T. H. B. M.
    Singh, Naveena
    Do, Viet
    D'Amico, Romerai
    Nout, Remi A.
    Feeney, Amanda
    Verhoeven-Adema, Karen W.
    Putter, Hein
    Creutzberg, Carien L.
    LANCET ONCOLOGY, 2018, 19 (03): : 295 - 309
  • [15] Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)
    Baiocchi, Glauco
    Mattos Cunha Andrade, Carlos Eduardo
    Ribeiro, Reitan
    Moretti-Marques, Renato
    Tsunoda, Audrey Tieko
    Alvarenga-Bezerra, Vanessa
    Lopes, Andre
    Rangel Costa, Ronaldo Lucio
    Kumagai, Lillian Yuri
    Badiglian-Filho, Levon
    Faloppa, Carlos Chaves
    Mantoan, Henrique
    De Brot, Louise
    Dos Reis, Ricardo
    Goncalves, Bruna Tirapelli
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (05) : 676 - 679
  • [16] 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
    Pivot, Xavier
    Romieu, Gilles
    Debled, Marc
    Pierga, Yves
    Kerbrat, Pierre
    Bachelot, Thomas
    Lortholary, Alain
    Espie, Marc
    Fumoleau, Pierre
    Serin, Daniel
    Jacquin, Jean-Philippe
    Jouannaud, Christelle
    Rios, Maria
    Abadie-Lacourtoisie, Sophie
    Venat-Bouvet, Laurence
    Cany, Laurent
    Catala, Stephanie
    Khayat, David
    Gambotti, Laetitia
    Pauporte, Iris
    Faure-Mercier, Celine
    Paget-Bailly, Sophie
    Henriques, Julie
    Grouin, Jean Marie
    LANCET, 2019, 393 (10191): : 2591 - 2598
  • [17] A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
    McLeod, D
    Zinner, N
    Tomera, K
    Gleason, D
    Fotheringham, N
    Campion, M
    Garnick, MB
    UROLOGY, 2001, 58 (05) : 756 - 761
  • [18] Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial
    Behroozian, Tara
    Milton, Lauren
    Karam, Irene
    Zhang, Liying
    Ding, Keyue
    Lou, Julia
    Gallant, Francois
    Rakovitch, Eileen
    Tran, William
    Soliman, Hany
    Leung, Eric
    Vesprini, Danny
    Szumacher, Ewa
    Chen, Hanbo
    Donovan, Elysia
    Lam, Jacqueline
    Spadafora, Silvana
    Wronski, Matt
    Lavoie, Chris
    Walde, Natalie
    Lam, Emily
    Wong, Gina
    McKenzie, Erin
    Ariello, Krista
    Kennedy, Samantha
    Shariati, Saba
    Carothers, Katherine
    Gonzales, Glen
    Kagan, Yulya
    Chow, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1250 - +
  • [19] Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda
    Katsaros, Dionyssios
    Bessette, Paul
    Haie-Meder, Christine
    Ottevanger, Petronella B.
    Ledermann, Jonathan A.
    Khaw, Pearly
    Colombo, Alessandro
    Fyles, Anthony
    Baron, Marie-Helene
    Kitchener, Henry C.
    Nijman, Hans W.
    Kruitwagen, Roy F.
    Nout, Remi A.
    Verhoeven-Adema, Karen W.
    Smit, Vincent T.
    Putter, Hein
    Creutzberg, Carien L.
    LANCET ONCOLOGY, 2016, 17 (08): : 1114 - 1126
  • [20] Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
    Kang, X.
    Xu, J.
    Zhang, R.
    Song, Y.
    Wang, Z.
    Zhang, B.
    Chen, X.
    Zheng, Q.
    Li, Y.
    Qin, J.
    Huang, J.
    Li, Y.
    He, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1072 - S1073
12345